ストックスクリーナーアプリを入手
0.074
1.33%
-0.001
前日終値:
$0.075
開ける：
$0.052
24時間の取引高:
19,175
Relative Volume:
0.52
時価総額：
$N/A
収益：
-
当期純損益:
$-2.98M
株価収益率:
-0.2857
EPS:
-0.259
ネットキャッシュフロー:
$-1.71M
1週間 パフォーマンス:
-1.33%
1か月 パフォーマンス:
+62.64%
6か月 パフォーマンス:
+85.00%
1年 パフォーマンス:
+27.89%
1日の値動き範囲:
$0.052
$0.074
1週間の範囲:
$0.052
$0.075
52週間の値動き範囲:
$0.0341
$0.1052
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Compare HEPA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.074 | 0 | 0 | -2.98M | -1.71M | -0.259 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-20 | 再開されました | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc (HEPA) 最新ニュース
Hepion (HEPA) grants interim CEO 1.35M options at $0.08 - Stock Titan
Hepion chair granted 1.35M options at $0.08 | HEPA Insider Trading - Stock Titan
Hepion Pharmaceuticals (HEPA) gives VP 1.35M options at $0.08 - Stock Titan
Hepion (HEPA) director awarded 299K stock options - Stock Titan
Hepion Pharmaceuticals (HEPA) awards director 299K stock options - Stock Titan
Hepion Pharmaceuticals (HEPA) awards 299K options to director - Stock Titan
Hepion Pharmaceuticals Appoints James Liddy to Board of Directors - Minichart
Hepion appoints James Liddy to its board - TradingView
Hepion (NASDAQ: HEPA) COO locks in 2M warrants at $0.06 - Stock Titan
Hepion (HEPA) chairman-led group builds 26M-share stake - Stock Titan
Black Global 5 Llc Net Worth (2026) - GuruFocus
Wednesday’s insider buys and sells: Hepion insiders invest $800K By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals, Inc. Q2 2026: Revenue $0 Net loss $(1.25M), EPS $(0.08) — 10-Q Summary - TradingView
Hepion Pharmaceuticals director Stetz buys $25,000 in common stock By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock By Investing.com - Investing.com Australia
Hepion Pharmaceuticals director Stetz buys $25,000 in common stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock By Investing.com - Investing.com South Africa
Hepion COO Sireesh Appajosyula buys $100,000 in common stock By Investing.com - Investing.com Nigeria
Hepion COO Sireesh Appajosyula buys $100,000 in common stock - Investing.com
Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock - Investing.com
Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock By Investing.com - Investing.com India
Hepion Pharmaceuticals (HEPA) director purchases 500K shares and 500K warrants - Stock Titan
Hepion Pharmaceuticals (NASDAQ: HEPA) director purchases 2M shares and 2M warrants - Stock Titan
Hepion Pharmaceuticals (HEPA) interim CEO Stetz buys 4M shares and warrants - Stock Titan
Hepion Pharmaceuticals (HEPA) chair LoPriore reports 20M-share and warrant purchases - Stock Titan
Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock - Investing.com
Hepion Pharmaceuticals (HEPA) holder reports 10M warrants and 10M shares - Stock Titan
Darin Feinstein Discloses Investment at Hepion Pharmaceuticals with 11.1% Stake - TradingView
Investor buys 10M Hepion Pharmaceuticals (HEPA) shares plus warrant - Stock Titan
Hepion Pharmaceuticals (HEPA) completes $3.06M exempt securities sale under Rule 506(b) - stocktitan.net
Hepion Pharmaceuticals Announces New Private Placement Financing - TipRanks
Hepion Pharmaceuticals, Inc. announced that it has received $3.055 million in funding - marketscreener.com
Hepion Pharmaceuticals, Inc. Revenue Breakdown – OTC:HEPA - TradingView
Hepion Pharmaceuticals, Inc. Revenue Breakdown – OTC:CTRVP - TradingView
Hepion Pharmaceuticals (HEPA) Proxy Filing Summary - Quartr
Hepion Pharmaceuticals (HEPA) Proxy filing Summary - Quartr
Hepion Pharmaceuticals (HEPA) Q4 2025 earnings summary - Quartr
Hepion Pharmaceuticals (HEPA) director Stetz submits initial insider Form 3 - Stock Titan
Hepion Pharmaceuticals (HEPA) director Danina Fisher files initial Form 3 - Stock Titan
Hepion Pharmaceuticals keeps the focus on its pipeline - AD HOC NEWS
Two new directors join Hepion Pharmaceuticals (OTC: HEPA) board - Stock Titan
Hepion Pharmaceuticals updates CRV431 liver program, shares follow biotech peers - Ad-hoc-news.de
Enterprise value to revenue forward of Hepion Pharmaceuticals, Inc. – OTC:HEPA - TradingView
Hepion Pharmaceuticals, Inc. Actuals & Estimates (OTC:HEPA) - TradingView
Enterprise value to EBIT forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView
Price to book forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView
Price to sales forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView
Price to earnings forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView
Hepion Pharmaceuticals Inc (HEPA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Hepion Pharmaceuticals Inc (HEPA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Hepion Pharmaceuticals Inc (HEPA) 財務データ
収益
当期純利益
現金流量
EPS
0.07%
1.21%
大文字化:
|
ボリューム (24 時間):